AI assistant
Sending…
Climb Bio, Inc. — Director's Dealing 2022
Jan 31, 2022
33982_dirs_2022-01-31_387fbd14-ddbc-4193-a9f6-f38ae2c292f2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Eliem Therapeutics, Inc. (ELYM)
CIK: 0001768446
Period of Report: 2022-01-27
Reporting Person: Azelby Robert (Director, President & CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-01-27 | Stock Option (Right to Buy) | $8.21 | A | 500000 | Acquired | 2032-01-26 | Common Stock (500000) | Direct |
Footnotes
F1: For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/48th of the shares will vest on each monthly anniversary of January 27, 2022.
More from Climb Bio, Inc.
Regulatory Filings
2026
May 29
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Regulatory Filings
2026
May 5
Capital/Financing Update
2026
Apr 28
Board/Management Information
2026
Apr 3
Director's Dealing
2026
Feb 27
Major Shareholding Notification
2026
Feb 17
Director's Dealing
2026
Feb 17
Director's Dealing
2026
Jan 8